What is GRAIL, Inc.'s market cap?

GRAIL, Inc. (GRAL) has a market capitalization of $2.9B and trades on XNAS.

What is GRAIL, Inc.'s revenue and profitability?

GRAIL, Inc. generated $156.1M in trailing twelve-month revenue with a net loss of $395.3M, representing a net margin of -253.2%, with free cash flow of -$292.3M. These figures are based on the Q1 2026 filing.

Who are GRAIL, Inc.'s competitors?

GRAIL, Inc.'s key competitors include Guardant Health, Inc., Abbott Laboratories, Natera, Inc., and others. These companies compete in similar markets and product categories.

Who does GRAIL, Inc. partner with?

GRAIL, Inc.'s notable partners include Illumina, Inc., Quest Diagnostics, Epic Systems, and others.

Where is GRAIL, Inc. headquartered?

GRAIL, Inc. is headquartered in United States of America and employs approximately 1,170 people. It has been publicly traded since 2024.

GRAIL, Inc.

GRAL

GRAIL is a commercial-stage healthcare company that develops and commercializes multi-cancer early detection (MCED) technology.

Market cap

$2.91B+140%

Revenue$156.1M+19.4%

Net income-$395.3M+79.4%

Free cash flow-$292.3M+37.5%

EPS (diluted)-$10.31+82.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$40.8MBeat by $1.6M EPS-$2.29Beat by $0.47

Read the full report

Next report

Aug 11, 2026 (In 2 weeks)

Revenue estimate$42.4M

EPS estimate-$2.66

Financials

Q1 2026

Income statement

See full

Revenue$40.8M+28.1%

Operating income-$135.8M+11.6%

Net income-$93.2M+12.3%

EPS (diluted)-$2.29+26.1%

Balance sheet

See full

Cash & equivalents$76.3M-44.4%

Total debt$51.0M-20.7%

Total equity$2.5B+3.6%

Total assets$2.8B-1.5%

Cash flow

See full

Operating cash flow-$87.0M+8.4%

CapEx$503.0K+711%

Free cash flow-$87.5M+8.0%

Valuation & ratios

Valuation

See full

Market cap$2.91B+140%

Enterprise value$2.89B+121%

P/S18.7×+8.4×

Profitability

See full

Operating margin-348.7%-153pp

Net margin-253.2%-115pp

FCF margin-187.2%-60.4pp

Returns & leverage

See full

Return on equity-16.1%—

Debt / equity0×0.0×

Current ratio11.7×+2.0×

Segments

By product

See full

Screening revenue$39.8M+36.7%

Development Services$953.0K-64.8%

By segment

See full

Reportable Segment$40.8M+28.1%

Competitors

By market cap

Abbott$179.51B-18.5%

Natera, Inc.$37.5B+97.8%

Guardant Health$19.5B+255%

Tempus AI, Inc.$7.7B-31.1%

GRAIL, Inc.$2.9B+101%

Myriad Genetics$529.9M+29.2%

ADV

Advanced Biomed Inc. Common Stock$31.4M+190%

ONC

Onconetix, Inc.$3.0M+40.0%

By revenue growth

Tempus AI, Inc.+69.8%

Guardant Health+39.6%

Natera, Inc.+36.6%

GRAIL, Inc.+19.4%

Abbott+8.1%

Myriad Genetics-0.3%

By net margin

Abbott11.65%-20.8pp

Natera, Inc.-14.61%-3.2pp

Tempus AI, Inc.-22.2%+66.1pp

Guardant Health-40.1%+13.7pp

Myriad Genetics-48.24%-36.0pp

GRAIL, Inc.-253.22%+1,211pp

Profile

GRAIL is a commercial-stage healthcare company that develops and commercializes multi-cancer early detection (MCED) technology. The company's core value proposition is the Galleri test, a blood-based screening tool that identifies a shared cancer signal across more than 50 types of cancer and predicts the tissue of origin. By leveraging a proprietary targeted methylation platform and machine learning, the company aims to shift the paradigm toward early cancer detection at a population scale.

Competitive position

GRAIL is a pioneer and commercial leader in the MCED market with the largest clinical program in genomic medicine to date. It maintains a first-mover advantage with significant real-world data and established partnerships across multiple commercial channels.

GeographiesUnited States, United Kingdom, Israel, Canada, South Korea

Customer segmentsEnterprise, Government, Healthcare Providers, Consumers

Business modelDirect-to-consumer, B2B, Laboratory Developed Test (LDT), Licensing

SuppliersNext-generation sequencing (NGS) hardware, Laboratory reagents, Specialized blood collection tubes, DNA probes, Cloud computing infrastructure

CustomersSelf-insured corporations, Public health systems (NHS), Commercial health insurers, Concierge medical practices, Biopharmaceutical research departments

CountryUnited States of America

Listed2024

Employees1.2K

CEOJoshua J. Ofman

SectorHealthcare

IndustryBiotechnology

Websitegrail.com

FilingsSEC EDGAR

Ask your AI about GRAIL, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GRAIL, Inc.'s market cap?: GRAIL, Inc. (GRAL) has a market capitalization of $2.9B and trades on XNAS.
What is GRAIL, Inc.'s revenue and profitability?: GRAIL, Inc. generated $156.1M in trailing twelve-month revenue with a net loss of $395.3M, representing a net margin of -253.2%, with free cash flow of -$292.3M. These figures are based on the Q1 2026 filing.
Who are GRAIL, Inc.'s competitors?: GRAIL, Inc.'s key competitors include Guardant Health, Inc., Abbott Laboratories, Natera, Inc., and others. These companies compete in similar markets and product categories.
Who does GRAIL, Inc. partner with?: GRAIL, Inc.'s notable partners include Illumina, Inc., Quest Diagnostics, Epic Systems, and others.
Where is GRAIL, Inc. headquartered?: GRAIL, Inc. is headquartered in United States of America and employs approximately 1,170 people. It has been publicly traded since 2024.